Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)

This randomized clinical trial aims to evaluate the impact of a structured low-intensity exercise program on cognitive function in adult cancer patients undergoing chemotherapy. The study enrolls 100 participants who are randomly assigned to either a standard care group or an exercise intervention group. Cognitive function is measured using the Montreal Cognitive Assessment (MoCA) at baseline, 6, 9, and 12 months. Participants in the intervention group are instructed to double their baseline daily step count, tracked via pedometer, while those in the control group maintain their usual activity. All patients are given the pedometer for one week prior to the start of chemo to monitor their step count and determine their baseline. The study also collects self-reported data on cognitive difficulties and psychological well-being. The primary objective is to determine whether regular physical activity mitigates chemotherapy-related cognitive decline ("chemo brain") and whether MoCA scores correlate with patients' subjective experiences. This low-cost, home-based approach may offer an accessible strategy for preserving cognitive function during cancer treatment.

NCT Number	NCT06950190
Lead Sponsor	Ellis Medicine
Conditions	Chemotherapy-related Cognitive Impairment
Enrollment	100 participants
Start Date	2025-06-09
Primary Completion	2027-02-20 (estimated)
Study Completion	2027-02-20 (estimated)
Updated on ClinicalTrials.gov	2025-08-12